logo
logo
ASND stock ticker logo

Ascendis Pharma A/S

NASDAQ•ASND
CEO: Mr. Jan Moller Mikkelsen
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2015-01-28
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Contact Information
Tuborg Boulevard 12, Hellerup, 2900, Denmark
45-70-22-22-44
ascendispharma.com
Market Cap
$13.96B
P/E (TTM)
-53.1
17.4
Dividend Yield
--
52W High
$248.60
52W Low
$124.06
52W Range
83%
Rank55Top 80.0%
2.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$285.45M+0.00%
4-Quarter Trend

EPS

-$0.63+0.00%
4-Quarter Trend

FCF

$78.44M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Revenue Surge Driven by YORVIPATH Total revenue €720.1M, up €356.5M; YORVIPATH sales €477.4M, up €448.7M compared to 2024.
Operating Loss Significantly Reduced Operating loss €136.3M, improvement €142.5M versus prior year's €278.8M loss reported for 2024.
Positive Operating Cash Flow Cash flow from operations €53.9M, a €360.1M improvement from prior period cash usage of €306.2M.
Pipeline Milestones Achieved Secured Novo Nordisk deal; TransCon CNP NDA priority review with FDA PDUFA goal February 28, 2026.

Risk Factors

Future Viability Concerns Significant future losses incurred, making future viability assessment difficult; total equity deficit €162.8M.
Financing Dependency Risk Failure to secure needed capital could force delay, limit, or cease commercialization activities and product development.
Product Success Uncertainty Substantial dependence on product candidates succeeding in clinical trials or receiving necessary regulatory approval.
Supply Chain Single Source Reliance on third-parties for manufacturing, including single-source suppliers, risks material adverse business impact.

Outlook

Vision 2030 Blockbuster Goal Pursue Vision 2030 goal: achieve >€5B revenue for key products via worldwide commercialization efforts.
Pipeline Expansion Focus Expand pipeline in Endocrinology Rare Disease and pursue TransCon opportunities in >€5B indications.
Global Commercialization Execution Execute integrated organization strategy across US, Europe Direct, and International Markets for product launches.
Technology Platform Leverage Maximize value creation by leveraging TransCon technology platform through strategic collaborations with market leaders.

Peer Comparison

Revenue (TTM)

BAX stock ticker logoBAX
$11.24B
+5.7%
BMRN stock ticker logoBMRN
$3.22B
+12.9%
RPRX stock ticker logoRPRX
$2.38B
+5.1%

Gross Margin (Latest Quarter)

RPRX stock ticker logoRPRX
100.0%
+0.0pp
IONS stock ticker logoIONS
96.1%
-0.7pp
EXEL stock ticker logoEXEL
95.6%
+0.1pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
MRNA$22.10B-7.8-30.1%15.5%
ROIV$21.17B-25.5-18.3%4.0%
RPRX$20.00B26.211.9%45.6%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
39.0%
Strong Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
50%
Cash Flow Needs Attention

Deep Research

Next earnings:Apr 29, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data